RxAll, a Nigerian startup, has developed a portable drug authenticator that determines the authenticity of medications. It is a potentially powerful tool in the fight against the counterfeit drug market which is a multibillion-dollar industry that puts lives at risk. RxAll allows anyone to test the quality of a drug by using a portable nanoscanner and mobile app.?The proprietary machine learning algorithm reads the scan from the scanner, identifies the drug, assesses its quality and lets the user know whether the drug is real or counterfeit, in about 20 seconds. www.rxall.net

Amazon just announced new skills of their electronic assistant ?Alexa? that enables users to monitor their health conditions. Alexa is able to relay and store blood sugar measurement, schedule doctor?s appointments, and pass on prescription delivery updates by securely accessing users? private medical information. Amazon also ensures to protect users? privacy according to the Health Insurance Portability and Accountability Act. https://www.wired.com/story/alexa-whats-my-blood-sugar-level/

Global Kinetics, a startup based in Melbourne, has developed a wearable device called the Parkinson?s KinetiGraph (PKG) which continuously tracks the symptoms of Parkinson?s disease. It is designed for patients to wear for 6-10 days at a time, with the data then used to better inform doctors about how to manage and treat their patients. PKG is reported to be the first tech to provide an objective record of a Parkinson?s patient?s symptoms over time. www.globalkineticscorporation.com.au

Currently, most medical treatments are provided to people?after?the onset of disease symptoms, regardless of their genetic background. As a result, people may receive treatments too late to be effective and, in some cases, unsuitable treatments are administered. Proprietary tests developed by Advanced Genetic Diagnostics, a participant in the CSIRO ON program, can be applied years?before?the development of chronic disease symptoms. Earlier treatment of high risk people could save lives. They are currently seeking investors to market their test across the globe. www.advancedgenetictests.com

Whilst considered relatively benign, abscesses are a significant precursor to major medical adverse outcomes. Innova Medical, a participant in the CSIRO ON program, has developed a sterile, single use device that offers a complete solution for out-of-theatre management of abscesses; the device comprises skin penetration, drainage, and collection management components in a convenient package. www.inovamedical.com.au